Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20–45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial

•A novel 4-valent vaccine induces good immune response to HPV types 6/11/16/18.•A newly developed 9-valent HPV vaccine was highly immunogenic.•Both of the investigated vaccines were generally well tolerated among females 20–45 years old.•The new vaccines show non-inferiority in immunogenicity and safety comparing with Gardasil-4.